PS-341, a proteasome inhibitor for cancer treatment.

被引：0
|
作者：
Adams, J [1 ]
机构：
[1] Millennium Pharmaceut Inc, Drug Discovery, Cambridge, MA 02139 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2001年 / 222卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
157-MEDI
引用
收藏
页码：U665 / U665
页数：1
相关论文
共 50 条
  • [1] The proteasome inhibitor PS-341 in cancer therapy
    Teicher, BA
    Ara, G
    Herbst, R
    Palombella, VJ
    Adams, J
    [J]. CLINICAL CANCER RESEARCH, 1999, 5 (09) : 2638 - 2645
  • [2] Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer
    Adams, J
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (04) : 493 - 500
  • [3] Development of the proteasome inhibitor PS-341
    Adams, J
    [J]. ONCOLOGIST, 2002, 7 (01): : 9 - 16
  • [4] Current clinical trials for the proteasome inhibitor PS-341
    不详
    [J]. ONCOLOGY-NEW YORK, 2000, 14 (11): : 1589 - +
  • [5] Proteasome inhibition in cancer: Development of PS-341
    Adams, J
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (06) : 613 - 619
  • [6] Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer
    Mack, PC
    Davies, AM
    Lara, PN
    Gumerlock, PH
    Gandara, DR
    [J]. LUNG CANCER, 2003, 41 : S89 - S96
  • [7] The proteasome inhibitor, PS-341, causes cytokeratin aggresome formation
    Bardag-Gorce, F
    Riley, NE
    Nan, L
    Montgomery, RO
    Li, J
    French, BA
    Lue, YH
    French, SW
    [J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2004, 76 (01) : 9 - 16
  • [8] Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
    Zou, W
    Yue, P
    Lin, N
    He, M
    Zhou, ZM
    Lonial, S
    Khuri, FR
    Wang, BH
    Sun, SY
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (01) : 273 - 280
  • [9] Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy
    Lara, PN
    Davies, AM
    Mack, PC
    Mortenson, MM
    Bold, RJ
    Gumerlock, PH
    Gandara, DR
    [J]. SEMINARS IN ONCOLOGY, 2004, 31 (01) : 40 - 46
  • [10] Proteasome inhibitor PS-341 and docetaxel: sequence of administration may be crucial
    Garfield, D
    [J]. LANCET ONCOLOGY, 2001, 2 (12): : 714 - 714
12345